Article
Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.
PLoS medicine - 1 Dec 2016
Parkinson Christine A, Gale Davina, Piskorz Anna M, Biggs Heather, Hodgkin Charlotte, Addley Helen, Freeman Sue, Moyle Penelope, Sala Evis, Sayal Karen, Hosking Karen, Gounaris Ioannis, Jimenez-Linan Mercedes, Earl Helena M, Qian Wendi, Rosenfeld Nitzan, Brenton James D
Abstract excerpt
BACKGROUND: Circulating tumour DNA (ctDNA) carrying tumour-specific sequence alterations may provide a minimally invasive means to dynamically assess tumour burden and response to treatment in cancer patients. Somatic TP53 mutations are a defining feature of high-grade serous ovarian carcinoma (HGSOC). We tested whether these mutations could be used as personalised markers to monitor tumour burden and early...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.